

Right to Heal Foundation

FAQ

FAQs

Q. What is the relationship between RTH Foundations and BCM, Participating Countries, Hospitals and Surgeons?

A. For a description of the function and purpose of the RTH Foundation, click on the [About] tab. For a description of the function and purpose of BCM Industries, visit the BCM website [BCM Website].

BCM Industries is an emerging leader in the creation and delivery of regenerated human organ tissue replacements. The RTH Foundation is an international organization that administers the activities associated with finding, selecting and assisting candidate patients in receiving regenerated human organ tissue replacements. The RTH Foundation also administers all activities associated with the participating countries, hospitals, surgeons and medical teams needed to perform a specific organ tissue replacement procedure.

Q. Why and how has BCM been able to successfully deliver at Regenerative Medicine (RM) and global tissue replacement services; when others have failed?

A. There are many factors and reasons which have allowed BCM to emerge as a leader in human organ tissue regeneration and replacement. Some of the reasons and a brief description of each is provided in the Article titled: "Why and How did BCM become the emerging leader in human organ tissue Regenerative and Replacement Healing." To access this Article click on the [Knowledge Base] tab.

Q. Why did the RTH Foundation and BCM select the liver, kidneys, lungs, pancreas and skin as the first group of human organs to receive tissue replacement services?

A. The liver is a soft tissue organ that has some capabilities of organ tissue regeneration. It was therefore a beneficial organ for the first group. The BCM team has a long history of success in skin regeneration grafting. The other organs are all soft tissues organs with high demand for the delivery of tissue replacement services.

Q. Will the RTH Foundation and BCM address and deliver tissue replacement services for other human organs and human disease and injuries?

A. The intention is to follow this initial group of human organ tissue replacement services with from 3 to 5 more groups of advancements in human organ tissue regenerative and replacement healing deliveries. Some of these future regenerative replacement groups will focus on addressing diseases and various types of injuries.

Q. Why is the RTH Foundation bypassing the US and some of the developed countries and utilizing a few selective countries as the main approved countries for the delivery of regenerative replacement healing services?

A. The mission of the RTH Foundation is to begin accelerated volume delivery of BCM developed regenerative organ tissue replacements to needing individuals as soon as practical. To achieve that goal, RTH Foundation selects countries, hospital, surgeons and medical teams that are in the forefront of advancing regenerative replacement medicine. The US and many other countries currently are not leading the delivery of this new type of replacement healing.

Q. How long does it take to create and deliver a patient specific regenerative organ tissue replacement?

A. After the candidate patient and all of the participating parties agree and approve a candidate patient, and the BCM processing center receives the approved patient's dominated organ cells to support the cell growing regeneration procedure, the production process begins.

The production processing time, including the shipping time to the hospital that is to perform the tissue replacement delivery, is approximately 35 to 40

days from receipt of the patient's donated organ cells. During this production processing and tissue delivery time period, the patient needs to travel to the country and hospital that is to perform the tissue replacement procedure.

Q. When will human trials commence on the first group of human organs and after trials are completed what is the planned rate of delivery of regenerative organ tissue replacement?

A.The production data and delivery schedules are provided as a general guide only. There are many independent factors which impact the scheduling and delivery of human organ tissue replacements procedures. BCM and the RTH Foundation are estimating human regenerative organ tissue replacement trials for human livers could commence in the fourth quarter of 2020. Once the first few human trials are successfully completed BCM can accelerate production and delivery of liver tissue replacements. Within a few years the potential delivery rates through the RTH Foundation could reach more than 100,000 individual patient liver tissue replacements annually.

In regard to kidneys and lungs organ tissue replacements. Initial human trials could commence in the first quarter of 2021. Within a few years, following completions of successful human trials, BCM may be able to support a combined, both kidney and lung tissue replacement shipments, of between 50,000 to 100,000 deliveries annually.

The 5-year or longer-term goal of BCM and the RTH Foundation is to produce from 300,000 to 500,000 regenerative organ tissue replacements deliveries annually.

Q. What are the factors and considerations used by RTH Foundation, the hospitals, the surgeons and the medical teams to select a patient for regenerative organ tissue replacement?

A.The patient selection procedures and approval processes includes many factors and conditions. The selection is by a joint committee-based decision process. Here is a list of some of the factors considered by the committee members:

The candidate Patient demonstrates the need for regenerative organ tissue replacement treatment.....through one or more of these factors:

- 1] Has a serious disease or condition, or whose life is immediately threatened by their disease or condition.
- 2] Has no immediate plan or opportunity to receive an organ transplant.
- 3] Has previously received an animal or human organ transplant and the procedures has failed to fully address the required healing.
- 4] Has no satisfactory alternative therapy for treatment of the disease, injury or condition.
- 5] Has a disease, injury or condition where the regenerative organ tissue replacement treatment benefits justify the potential risks of treatment.
- 6] Has a risk of further deterioration or degradation in quality of life.
- 7] Has been placed under Hospice care.
- 8] Has indicated an acceptance to travel to a foreign country to receive the treatment.
- 9] Has other factors which indicate a clear need for the treatment.

Q. How does an individual, who needs or desires an organ tissue regenerative replacement, apply as a candidate for consideration to participate in human trials or to receive the procedures following the human trials period?

A. The application process and the initial screening of possible candidates for human trials and for follow-up, post-trials phase, delivery of regenerative organ tissue replacements is by submitting ones interest using the “Organ List Signup Form.” Anyone from any country can submit a name and information.

Q. How does one know if they are being considered to participate and what additional information is required of a potential candidate?

A. When a party who has submitted information into the “Organ List Signup Form.”is selected for further consideration as a potential human trial candidate, or a post human trials follow-up recipient of a regenerative replacement procedure, the party will be contacted by the RTH Foundation. At that time additional data will be requested and full and complete details of the procedures, process and all activities will be explained and provided.

Q. To accelerate the availability and delivery of regenerated human organ tissue replacements, the RTH Foundation has selected and approved a few counties for delivery of this tissue replacement service. Delivery of this treatment is relying upon travel to another country. How safe and effective is this medical tourism approach?

A. Medical tourism refers to patient-tourists who travel from a country to another in order to seek some sort of healthcare services. In the past three decades, medical tourism became a global phenomenon that has attracted both capital invest and governments to adopt policies for promoting medical tourism in respective countries.

Historically, medical travelers were from developing countries seeking to obtain medical care in the advanced healthcare centers in the developed countries. However, due to rapid increases in healthcare costs, unavailability of affordable healthcare insurance, long waiting times, non-insurance covered medical services and other factors have driven the need and demand for alternative countries that can satisfy the demand.

To demonstrate the effectiveness and soundness of this approach, the estimated global market size of this industry is \$65-87.5 billion, based on approximately 20-24 million cross-border patients worldwide. The current estimate is that 1.9 million Americans will travel outside the US for medical care during 2019. This is a mature industry prepared to accept and support RTH Foundation delivery of human organ tissue replacement treatments.

>>>><<<<